Early infant diagnosis of HIV infection in low-income and middle-income countries: does one size fit all?
Despite expansion of services for prevention of mother-to-child transmission of HIV (PMTCT), about 700 infants acquire HIV every day. Early initiation of antiretroviral therapy for HIV-infected infants reduces mortality but requires diagnosis by virological testing, which is complex, expensive, and inaccessible in many settings. Little cost-effectiveness evidence exists about different strategies to deliver early infant diagnosis services. Cost-effectiveness will vary depending on entry points for testing, underlying prevalences of HIV, PMTCT coverage, treatment availability, programme attrition, and other factors. Appropriate policy responses are therefore context-specific. In most cases, early infant diagnosis should be concentrated at entry points where underlying infant HIV prevalence is highest (eg, malnutrition wards). This strategy contrasts with the tendency at present to test mainly within PMTCT programmes. If testing is undertaken in PMTCT programmes with high coverage, addition of a virological test at birth might have advantages, including greater predictive value, earlier diagnosis, and better infant follow-up. National programme managers should recognise the opportunity costs of the limited resources available, acknowledge the changing scenario of PMTCT scale-up, ensure implementation of provider-initiated testing and counselling, and tailor early infant diagnosis programmes to maximise health gains for children.
MRC Clinical Trials Unit, London, UK. Electronic address: martina.penazzato@gmail.com.
Martina
M
Penazzato
Centre for Health Economics, University of York, York, UK.
Paul
P
Revill
MRC Clinical Trials Unit, London, UK; Centre for Paediatrics, Blizard Institute, Queen Mary University of London, London, UK; Zvitambo Institute for Maternal Child Health Research, Harare, Zimbabwe.
Andrew J
AJ
Prendergast
MRC Clinical Trials Unit, London, UK.
Intira J
IJ
Collins
Centre for Health Economics, University of York, York, UK.
Simon
S
Walker
STD/AIDS Control Program, Ministry of Health, Kampala, Uganda.
Peter J
PJ
Elyanu
Centre for Health Economics, University of York, York, UK.
Mark
M
Sculpher
MRC Clinical Trials Unit, London, UK.
Diana M
DM
Gibb
D000367:Age Factors; D003362:Cost-Benefit Analysis; D003906:Developing Countries; D042241:Early Diagnosis; D015658:HIV Infections / Q000175:diagnosis* / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control